Macular Degeneration Treatment Market Report 2026

The macular degeneration treatment market size has grown rapidly in recent years. It will grow from $12.38 billion in 2025 to $13.81 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to aging global population, increased prevalence of age-related macular degeneration, clinical success of anti-vegf injections, improved ophthalmic diagnostic capabilities, growing access to specialized eye care services.

The macular degeneration treatment market size is expected to see rapid growth in the next few years. It will grow to $20.74 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rising elderly population worldwide, increasing investment in advanced retinal therapies, growing focus on early-stage amd management, expanding adoption of gene and regenerative therapies, higher healthcare spending on vision care. Major trends in the forecast period include rising focus on early diagnosis and disease progression control, growing adoption of anti-vegf therapies, increasing demand for long-term vision preservation treatments, expansion of minimally invasive treatment options, rising awareness of age-related eye disorders.

The rising prevalence of retinal disorders is expected to drive the growth of the macular degeneration treatment market. Retinal disorders impact the essential tissue of the eye and alter how individuals perceive visual information, resulting in distorted or lost vision. For example, according to the American Academy of Ophthalmology, by 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, a broad term for a group of eye disorders, with the highest prevalence among individuals aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Consequently, the increasing prevalence of retinal disorders is fueling the growth of the macular degeneration treatment market.

Major companies operating in the macular degeneration treatment market are concentrating on developing biosimilars for age-related macular degeneration (AMD) to enhance access to effective therapies. Biosimilars are biological medical products that are highly similar to an already approved reference product, with no clinically meaningful differences in safety, purity, or potency. For example, in May 2024, Biocon Biologics Ltd, an India-based company, and Samsung Bioepis Co. Ltd, a South Korea-based company, received FDA approvals for Yesafili and Opuviz, two new biosimilars. Both biosimilars inhibit vascular endothelial growth factor (VEGF), which causes abnormal blood vessel growth in the eye. This mechanism helps prevent vision loss associated with conditions such as AMD and diabetic retinopathy. The FDA's approval process included comparative studies demonstrating that Yesafili and Opuviz have no significant differences in efficacy or safety compared to Eylea. These studies involved thorough evaluations of the biosimilars' pharmacokinetics and immunogenicity.

In July 2023, Harrow Inc., a US-based company, acquired Santen for $8 million. Through this acquisition, Harrow aims to expand its portfolio by integrating Santen's expertise in macular degeneration treatment. Santen Pharmaceutical Co., Ltd. is a Japan-based company that provides macular degeneration therapies.

Major companies operating in the macular degeneration treatment market are F Hoffmann La Roche Ltd, Regeneron Pharmaceuticals Inc, Novartis AG, Bayer AG, Allergan Inc, Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio Inc, Aerie Pharmaceuticals Inc, Kodiak Sciences Inc, Neurotech Pharmaceuticals Inc, Regenxbio Inc, Adverum Biotechnologies Inc, Applied Genetic Technologies Corp, 4D Molecular Therapeutics Inc, GenSight Biologics SA, Nanoscope Therapeutics Inc, Annexon Inc, Ocular Therapeutix Inc, Graybug Vision Inc.

North America was the largest region in the macular degeneration treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the macular degeneration treatment market by increasing costs associated with imported anti-vegf drugs, ophthalmic surgical devices, and advanced diagnostic equipment. These effects are more pronounced in injectable therapy and late-stage amd treatment segments, particularly in asia-pacific and europe where supply chains are globally interconnected. Hospitals and ophthalmic clinics face higher treatment and procurement costs. However, tariffs have encouraged local manufacturing of ophthalmic drugs, regional sourcing of medical devices, and investments in domestic eye care infrastructure, supporting long-term market resilience.

The macular degeneration treatment market research report is one of a series of new reports that provides macular degeneration treatment market statistics, including macular degeneration treatment industry global market size, regional shares, competitors with a macular degeneration treatment market share, detailed macular degeneration treatment market segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The macula is the central part of the retina, a light-sensitive layer of tissue located at the back of the eye, and it is responsible for central vision. Degeneration of the macula, which affects the central portion of the retina and leads to distortion or loss of central vision, most commonly occurs after the age of 60 and is known as age-related macular degeneration (AMD). Macular degeneration treatment is used to manage this eye disease, slow its progression, and prevent severe vision loss.

The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula undergoes changes, with medium-sized drusen deposits and no pigment alterations, but vision remains unaffected. Intermediate AMD occurs when vision may become blurry or wavy due to large drusen or pigment changes. In late-stage AMD, central vision is completely lost, leading to severe vision impairment. The types of macular degeneration treatments include wet macular degeneration and dry macular degeneration. The routes of administration for macular degeneration treatments include oral, injectable, and others, which are used by various end users such as ambulatory surgical centers, ophthalmic clinics, and hospitals.

The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.